The two most consistent features of the diseases caused by trinucleotide repeat expansion-neuropsychiatric symptoms and the phenomenon of genetic anticipation-may be present in forms of dementia, hereditary ataxia, Parkinsonism, bipolar affective disorder, schizophrenia and autism. To identify candidate genes for these disorders, we have screened human brain cDNA libraries for the presence of gene fragments containing polymorphic trinucleotide repeats. Here we report the cDNA cloning of CAGR1, originally detected in a retinal cDNA library. The 2743 bp cDNA contains a 1077 bp open reading frame encoding 359 amino acids. This amino acid sequence is homologous (56% amino acid identity and 81% amino acid conservation) to the Caenorhabditis elegans cell fate-determining protein mab-21. CAGR1 is expressed in several human tissues, most prominently in the cerebellum, as a message of ∼3.0 kb. The gene was mapped to 13q13, just telomeric to D13S220. A 5′-untranslated CAG trinucleotide repeat is highly polymorphic, with repeat length ranging from six to 31 triplets and a heterozygosity of 87-88% in 684 chromosomes from several human populations. One allele from an individual with an atypical movement disorder and bipolar affective disorder type II contains 46 triplets, 15 triplets longer than any other allele detected. Though insufficient data are available to link the long repeat to this clinical phenotype, an expansion mutation of the CAGR1 repeat can be considered a candidate for the etiology of disorders with anticipation or developmental abnormalities, and particularly any such disorders linked to chromosome 13.
The two most consistent features of the diseases caused by trinucleotide repeat expansion-neuropsychiatric symptoms and the phenomenon of genetic anticipation-may be present in forms of dementia, hereditary ataxia, Parkinsonism, bipolar affective disorder, schizophrenia and autism. To identify candidate genes for these disorders, we have screened human brain cDNA libraries for the presence of gene fragments containing polymorphic trinucleotide repeats. Here we report the cDNA cloning of CAGR1, originally detected in a retinal cDNA library. The 2743 bp cDNA contains a 1077 bp open reading frame encoding 359 amino acids. This amino acid sequence is homologous (56% amino acid identity and 81% amino acid conservation) to the Caenorhabditis elegans cell fate-determining protein mab-21. CAGR1 is expressed in several human tissues, most prominently in the cerebellum, as a message of ∼3.0 kb. The gene was mapped to 13q13, just telomeric to D13S220. A 5′-untranslated CAG trinucleotide repeat is highly polymorphic, with repeat length ranging from six to 31 triplets and a heterozygosity of 87-88% in 684 chromosomes from several human populations. One allele from an individual with an atypical movement disorder and bipolar affective disorder type II contains 46 triplets, 15 triplets longer than any other allele detected. Though insufficient data are available to link the long repeat to this clinical phenotype, an expansion mutation of the CAGR1 repeat can be considered a candidate for the etiology of disorders with anticipation or developmental abnormalities, and particularly any such disorders linked to chromosome 13.
INTRODUCTION
Trinucleotide repeat expansion mutation, also known as dynamic mutation, is now known to cause nine human diseases (1) (2) (3) (4) . In *To whom correspondence should be addressed at: Department of Psychiatry, Johns Hopkins University School of Medicine, 618 Ross Research Building, 720 Rutland Avenue, Baltimore, MD 21205-2196, USA the Type I diseases, X-linked spinal and bulbar muscular atrophy (SBMA or Kennedy's disease) (5), Huntington's disease (HD) (6) , spinocerebellar atrophy type 1 (SCA1) (7), dentatorubral and pallidoluysian atrophy (DRPLA) (8) (9) (10) and Machado-Joseph disease (SCA III) (11) , a CAG repeat encoding glutamine expands from a normal range of ∼10-35 repeats to >35-40 repeats. These diseases are characterized by neurodegeneration, with typical disease onset in middle age. The androgen receptor, in which a CAG expansion causes SBMA, is a zinc finger domain transcription factor (12) . The normal function of the proteins encoded by the genes associated with the other four disorders is unknown and the proteins share no sequence homology other than the glutamine repeat. The mechanism by which repeat expansion causes these diseases is also unknown, though a variety of evidence suggests that an excessively long glutamine repeat leads to a toxic gain-of-function (13) (14) (15) (16) (17) (18) (19) .
The Type II repeat expansion mutation diseases include myotonic dystrophy (MD) (20) (21) (22) , the A (23-25) and E (26) forms of fragile X syndrome (FraXA and FraXE) and some forms of Jacobsen syndrome (27) . These diseases are characterized by CGG or CTG repeat expansions in untranslated regions. Normal repeat length in the associated genes ranges from five or six to ∼25 (FraXE), 37 (MD) and 42 (FraXA), though in the Jacobsen syndrome (CBL2) normal repeat length is limited to 11-14 repeats. Expansion beyond 200 repeats in Fragile X and 50-60 repeats in MD and Jacobsen syndrome (the latter through chromosomal deletion) leads to disease. Alleles intermediate between normal and disease length, termed premutations, are unstable in transmission but do not lead to a disease phenotype. The normal functions of the genes associated with the Type II diseases (except FraXE) are now at least partially understood. The FMR gene product (involved in FraXA) is believed to be an RNA binding protein associated with ribosomes (28) (29) (30) . MDK (myotonic dystrophy) is a protein kinase (31) and CBL2 (Jacobsen syndrome) is a proto-oncogene with a role in a receptor tyrosine kinase signal transduction pathway (32, 33) . In fragile X and myotonic dystrophy, the abnormal repeat reduces or eliminates normal transcription of the associated mRNA, or causes other RNA abnormalities (4) . In Jacobsen's syndrome, the repeat expansion leads to a deletion of a portion of chromosome 11 (27) .
Type I and Type II diseases share the phenomenon of genetic anticipation, in which symptom severity worsens or age of onset decreases in successive generations (though in Jacobsen syndrome, genotype but not phenotype becomes more abnormal). In addition, the pathology of each disease includes neurodegeneration or neurodevelopmental abnormalities. Other diseases that share these features, and that may therefore also stem from repeat expansion, include various forms of hereditary dementia, ataxia, Parkinsonism, spinocerebellar atrophy, bipolar affective disorder, autism and schizophrenia (34) (35) (36) (37) (38) (39) (40) . To establish candidate genes for these disorders, we and others have sought to identify and map cDNA fragments with polymorphic trinucleotide repeats expressed in the human brain (8, (41) (42) (43) (44) (45) (46) . As part of this effort, we now report a cDNA sequence mapping to 13q13 that encodes a peptide homologous to the Caenorhabditis elegans protein mab-21 and contains a highly polymorphic 5′-untranslated CAG repeat.
RESULTS
Clone CAGJM, containing a (CAG) 21 trinucleotide repeat, was serendipitously isolated by random sequencing of a human retina cDNA library as part of a search for novel genes expressed in the The sequence contains a long open reading frame encoding a 359 amino acid polypeptide, assuming translation initiation at the first methionine within the open reading frame. This sequence is 56% identical to the C.elegans mab-21 deduced amino acid sequence, with 81% amino acid conservation. The sequences share a start site, and the mab-21 sequence extends 27 amino acids beyond the CAGR1 sequence. CAGR1 residues 77-92 and 96-129 are identical to the mab-21 sequence, residues 42-53 and 275-285 differ at only one amino acid, and residues 302-322 differ at only two amino acids. Additional shorter stretches of amino acid identity are scattered throughout the sequence. The CAGR1 amino acid sequence has six deleted amino acids (between amino acids 58 and 59, 214 and 215 and 225 and 226) and an additional amino acid (246) compared with mab-21. Analysis of mab-21 and CAGR1 hydrophilicity indicates that the proteins have matching profiles with no significant regions of hydrophobicity. Search of GenBank and other servers revealed no clear homology to other known proteins.
Expression of the CAGR1 mRNA is depicted in Figure 3 . Northern blots were probed with a labelled antisense oligonucleotide specific for CAGR1. A single band was detected at ∼3.0 kb. Expression is higher in brain than in other tissues and, within the brain, expression is highest within the cerebellum. No signal was detected using a sense probe (data not shown).
CAGR1 was mapped to chromosome 13 using a chromosomalrodent hybrid panel. Using the polymorphic CAG repeat within CAGR1, linkage analysis was performed using four CEPH families to localize CAGR1 to the region of D13S220 (lod = 18.96, θ = 0). Radiation hybrid mapping further defined the region of CAGR1 to the telomeric side of D13S220, such that D13S220 is equidistant in radiation hybrid map units from the more centromeric marker D13S267 (0.114 units) and CAGR1 (0.119 units). The fragile site Fra13A has been localized to this general region.
The extent of length polymorphism of the CAG repeat within CAGR1, as determined by PCR across the repeat region in genomic DNA of specified populations, is depicted in Figure 4A . The distribution varied by both ethnicity and species. The modal repeat length in an East Anglian population was 13 triplets, over three times more common than the second most frequent repeat length. The modal length in an African population (primarily from Nigeria) was 22 triplets, only slightly more common than the next most frequent repeat length in this population. Heterozygosity was 87% in the East Anglican population and 88% in the Black African population. CAGR1 repeat length was examined in an additional 116 chromosomes from unrelated individuals in the CEPH collection (not shown). The distribution was nearly identical to that seen in the East Anglian population with repeat lengths ranging from nine to 25 triplets.
The length of the repeat in the chimpanzee is much less variable (25% heterozygosity) than in the human populations. Seven alleles contained 13 triplets, another seven contained 12 triplets, and two alleles contained 11 triplets. Repeat lengths in other primates also appeared shorter and less variable than in the human: four gorilla chromosomes each contained CAGR1 repeats with 14 triplets, six orangutan chromosomes each contained CAGR1 repeats with eight triplets, four baboon chromosomes each contained CAGR1 repeats with six triplets and four macaque chromosomes (two from a rhesus and two from a crab-eating macaque) each contained CAGR1 repeats with five triplets.
The length of the CAG repeat in CAGR1 was also tested in DNA from patients with bipolar affective disorder (N = 46), schizophrenia (N = 77), or a movement disorder with anticipation or phenotypic features similar to those in known triplet repeat disorders (N = 18) (Fig. 4B) , since repeat expansion has been postulated as the etiology for each of these conditions. In addition, repeat length was examined in 11 individuals with various other psychiatric conditions, including recurrent major depression, schizoaffective disorder and psychosis not otherwise specified. Allele distribution is similar to that seen in the specified human populations, though 13/334 (3.89%) of the patients and only 1/296 (0.34%) of the non-patients had alleles with >25 repeats. One markedly long repeat of 46 triplets was observed in a patient with gait ataxia, dystonic movements, abnormal eye movements and episodes of major depression and hypomania consistent with bipolar disorder type II. Though ascertained through an HD clinic, symptoms in the patient were not characteristic of HD. Except for this one allele, the repeat length in a total of 684 human chromosomes ranged from six to 31 triplets.
The detection by PCR of the allele with 46 repeats is depicted in Figure 5 . Several bands above the band of peak intensity are also apparent, similar to variation in the size of the PCR product of the expanded allele observed in expansion mutation diseases (48) (49) (50) . This cluster of PCR bands was visualized on an agarose gel and excised, subcloned and sequenced. The sequence confirms that this unusually long allele results from an increase in the number of CAG triplets, and not from an insertion or other sequence alteration. Repeat length ranged from 41 to 50 triplets in the eight subcloned colonies randomly selected for sequencing. The mother of the proband has two alleles of normal length (13 and 19 triplets); DNA from other first degree relatives is unavailable. Several non-first degree paternal relatives with clinical symptoms different from the proband, but characteristic of HD, have an expanded HD repeat and normal length CAGR1 alleles. The proband does not have an expanded HD allele in peripheral leukocytes (tested three times).
DISCUSSION
CAGR1, initially identified from a retinal cDNA library, encodes a 359 amino acid sequence homologous (56% identical and 81% conserved amino acids) to the C.elegans cell fate-determining protein mab-21. CAGR1 is located on chromosome 13q13, telomeric to marker D13S220, and is expressed most highly in the brain, particularly the cerebellum. A 5′-untranslated CAG trinucleotide repeat is highly polymorphic, ranging from six to 31 triplets in length in several populations, with one allele of 46 repeats detected in an individual with an idiopathic movement disorder and an affective disorder.
The primary clue concerning the function of CAGR1 is its homology to mab-21. mab-21 was first defined as a mutation resulting in abnormal development of one set of the nine pairs of peripheral sense organs, known as rays, found in the posterior of the male C.elegans (51) . In mab-21 mutants, ray 6 is absent and ray 4 is replaced by a larger fusion ray. A neural cell and a glia-like cell normally found in ray 6 assume the characteristics of homologous cells in ray 4, a ray 6 hypodermal cell fuses to the wrong partner cell, and another hypodermal cell develops into a neuroblast (52) . These abnormalities in the ray structure of the tail, and less fully characterized abnormalities of morphology, movement and reproduction, suggest that mab-21 acts to specify cell fate. mab-21 may act downstream from the HOM-C/Hox set of transcription factor genes, which regulate pattern formation on a global scale, to regulate cell fate on a local level (52) . It is possible that CAGR1 has a similar role; the pattern of CAGR1 expression suggests that the cerebellum is a site of CAGR1 action.
A number of human diseases arise from mutations in homologues to genes that regulate development in other species. For instance, translocations within a human homologue of the Drosophila notch gene, TAN1 (translocation-associated notch homolog), result in acute T-cell lymphoblastic leukemia (53) . It has been suggested that TAN1 may play a role in cell fate determination during hematopoiesis (54) . PAX3, a member of the family of 'paired-box' genes first identified as regulators of Drosophila segmentation, encodes a DNA binding protein important in early neurogenesis (55) . A point mutation in PAX3 leads to the mouse phenotype splotch, characterized by pigmentary abnormalities, spina bifida and exencephaly (56) . In humans, the Waardenburg syndrome, characterized by facial dysmorphia, pigmentary disturbance, and cochlear deafness (MIM 193500), arises from any one of a variety of mutations within HUP2, the human homolog of PAX3 (57) . PAX6, another member of the paired-box gene family, is critical to eye development in Drosophila, mice and humans (58) . Mutations in human PAX6 result in aniridia (59, 60) , other anterior segment malformations (61) and a form of keratitis (62) . A neonate with each PAX6 allele affected by a different nonsense mutation had no eyes and severe craniofacial and central nervous system abnormalities, similar to the phenotype observed in mice homozygous for a PAX6 mutation (63) . Mutations within the EMX2 homeobox gene, the human cognate of a gene expressed in proliferating neuroblasts of the developing mouse cerebral cortex, have recently been associated with schizencephaly, a disorder characterized by large clefts of the cerebral hemisphere (64) .
At least one disorder with developmental abnormalities, the Moebius syndrome, has been mapped to a location near CAGR1. Narrowly defined, the clinical features of this syndrome include 6th and 7th cranial nerve palsies and various skeletal defects, but numerous variations have been reported in >200 cases (65) . In seven individuals from one family, congenital 7th nerve palsy and digital contractures were associated with a 1p34:13q13 translocation (66) . An isolated case of Moebius syndrome associated with deletion of 13q12.2 has also been reported (67) , suggesting that mutations at a locus on 13q may be sufficient to cause at least some forms of the disorder. The location of CAGR1 raises the possibility that a mutation within this gene could be present in some of the reported cases. Interestingly, fragile site Fra13A has been mapped to a region near CAGR1, though at present there is no evidence implicating a CAG/CTG repeat in fragile site induction (27, 68) .
The normal allele distribution of CAGR1 appears to range from six to 31 triplets. African and and non-African populations have somewhat different allele distributions; most notably, the modal repeat length (13 triplets) in all non-African populations is present three times more frequently than the next most common allele, whereas no dominant modal length is present in the African population. This difference is consistent with previous findings that microsatellite allelic diversity in Africans exceeds that of other populations (69) . The generally shorter and less polymorphic CAGR1 repeats observed in non-human primates compared with humans is also consistent with a previous comparison of di-, tri-and tetranucleotide repeat length in primates (70) ; humans typically have longer repeats, suggesting that repeat length evolution is directional and occurs at variable rates in different species.
The extent of CAGR1 repeat polymorphism is strikingly similar to that seen in the repeats that expand to cause disease. CAGR1 resembles the genes associated with Type II disorders (FMR, CBL2 and MDK) since the repeat is not within a coding region of the gene. The analogy to these genes suggests that repeats with more than ∼40 or 50 triplets may be meiotically unstable (premutations), while biochemical and perhaps phenotypic abnormalities may result with repeat lengths in the range of 100-200 triplets (2, 5) . This makes the finding of one allele with a repeat length of 46, 15 triplets longer than the other 683 alleles tested, particularly provocative. Whether a relationship exists between the phenotype of the individual involved (an atypical movement disorder accompanied by bipolar affective disorder type II) and the repeat is impossible to ascertain at present. The long repeat may represent a rare normal variant or a premutation. Thus far, no other alleles with unusually long repeats have been detected in subjects with schizophrenia, affective disorder or a movement disorder. Nonetheless, expansion of the CAGR1 repeat remains an attractive candidate for the etiology of disorders with features of anticipation or developmental abnormalities, and particularly any such disorders linked to chromosome 13q.
MATERIALS AND METHODS

Initial identification of repeat
CAGJM, a clone with a short insert containing a (CAG) 21 trinucleotide repeat, was identified as part of a search for novel genes expressed in the retina [(47); J.P.M. and J.N., unpublished]. The search strategy involved isolating inserts from a human retinal cDNA library en masse by EcoRI cleavage and preparative gel electrophoresis. Inserts were then used as a template for DNA synthesis using the Klenow Escherichia coli polymerase I fragment and the primer 5′GACGAGATATTAGAATTCTACT-CGNNNNNN3′ (N = a combination of all four bases). After heat denaturation and a second cycle of priming, the primer 5′CCCCCCCCCGACGAGATATTAGAATTCTACTC3′ was used for PCR amplification of those inserts with the original primer incorporated into both ends. After EcoRI cleavage, isolation of 400-600 bp inserts, and recloning into λgt10, the library was plated at low density, and screened to eliminate repetitive or mitochondrial sequences. After PCR with primers flanking the λgt10 insertion sites, the products were sequenced (ABI, performed by Johns Hopkins Core Genetics Facility).
cDNA cloning
CAGJM was subcloned into pCRII using the TA cloning method (Invitrogen). An oligonucleotide (CAGR1.45: 5′GAATCCTT-GTGTGAGAGAACCGCATGGAGAGATCACCTTCTCGG3′) flanking the repeat was used to screen human cerebellar and cerebral cortex libraries (Stratagene) using standard methods (71) as we have previously described (8) . Libraries were plated at a density of ∼20 000-50 000 plaques per 150 mm plate. Duplicate supported nitrocellulose filters from each plate were lifted, denatured, neutralized, baked at 80_C and briefly washed in 2× SSC. Filters were then prehybridized in 50% formamide, 5× SSPE, 5× Denhardt's solution (0.1% Ficoll 400, 0.1% polyvinylpyrrolidone, 0.1% bovine serum albumin), 10 mg/ml denatured salmon sperm DNA, and 0.5% SDS for at least 1 h. Probes were labelled with [γ-32 P]ATP using polynucleotide kinase (New England Biolabs). Hybridization was in the same buffer for 38 h at 42_C. Filters were washed in 2× SSC and 0.5% SDS at 25_C for 30 min and then in 0.2× SSC/0.5% SDS at 56_C for 30 min. After an overnight exposure, positive plaques were selected and plaque purified. Plasmids (pBluescript SK) were excised using an in vivo excision procedure (Stratagene). Clones were fully sequenced on both strands using an ABI automated sequencing apparatus. Additional sequencing, with unique primers, was performed in the region surrounding the repeat to confirm the open reading frame. After clone alignment and determination of a final cDNA sequence using the application SequencherT (Gene Codes Corp.), a search for homologies to the nucleotide and conceptually translated amino acid sequences was performed against GenBank using blastn, blastp, blastx (72) , BEAUTY (73) and BLOCKS (74) . Hydrophilicity of the amino acid sequence was analysed using the Kyte-Doolittle scale as performed by the application MacVectorT (Eastman Kodak). The complete cDNA construction was termed CAGR1 (CAG repeat detected in a retinal library).
Polymorphism analysis
To detect repeat length variation in CAGR1, PCR was performed across the repeat region, using primers flanking the repeat (CAGJM-5′-1: 5′GATAAAAGGAAGGGAAAA3′, CAGJM-3′-1: 5′CAGAAATGGATCAAAAAT3′) and genomic DNA as templates. The East Anglian samples were from patients referred for testing of an HD expansion; the population is primarily of Northern European ancestry. The African samples were from patients with sickle cell anaemia, primarily from Nigeria (70) . DNA from individuals with schizophrenia and bipolar disorder was obtained from several sources: (i) probands with Diagnostic and Statistical Manual-III-Revised (DSM-III-R) (75) defined schizophrenia [using a modified Schedule for Affective Disorders and Schizophrenia interview (76) and multiple external sources of information] and a least one sib with either schizophrenia or schizoaffective disorder who were recruited from the United States, Great Britain and Italy as previously described (77) schizophrenia by DSM-III-R criteria), obtained and prepared as previously described (79) . CAGR1 repeat length was also tested in DNA from patients referred to Johns Hopkins or Cambridge for assessment of idiopathic movement disorders similar to those seen in the known trinucleotide repeat expansion diseases, but who did not have any of the known expansions. Repeat length was also assesed in DNA from 84 unrelated individuals obtained from the Centre d'Etude du Polymorphisme Humain (CEPH) collaborative.
PCR employed 40-100 ng of genomic DNA, 400 pM of each unlabelled primer, ∼40 pM of CAGJM 3′-1 radiolabelled with [γ-32 P]ATP, 200 µM dNTP, 1.5 mM MgCl 2 , and 0.2 units of Taq polymerase (Boehringer Mannheim) in a total reaction volume of 12.5 µl. After denaturation at 96_C for 2 min, the reaction consisted of 33 cycles of 96_C for 30 s, 52_C for 30 s and 72_C for 60 s, followed by a 7 min extension at 72_C. Product size was determined by electrophoresis on a 6% denaturing polyacrylamide-urea gel, and comparison with size markers and clones of known repeat length. Alternatively, primers were fluorescently labelled and product size measured on an ABI sequencing apparatus.
Chromosomal location
CAGR1 chromosomal location was determined by three independent methods. First, Panel 2 of DNA from NIGMS monochromosomal human-rodent hybrid cell lines was used as PCR template (80) to indicate that CAGR1 is located on chromosome 13. More precise localization was obtained by PCR using genomic DNA from CEPH families in which polymorphic markers have been mapped (81) . Two-point linkage analysis was performed using the LINKAGET program (82) between CAGR1 repeat length and known polymorphic loci on chromosome 13 in families 1331, 1362, 1413 and 884. For further definition of location, CAGR1 was mapped relative to loci D13S220 and D13S267 using a radiation hybrid panel (83) .
Northern analysis
Northern blots of total RNA derived from human brain tissue by the CsCl method or purchased (Clontech) were probed with an antisense oligonucleotide (5′TGCTTTTCCCTTCCTTTTATCTTTGAGCC-CAGCCGTTCT3′) at a hybridization temperature of 42_C in the buffer described above modified to include 10× Denhardt's solution and 2% SDS. The multiple tissue blot was washed at room temperature for 30 min with 2× SSC/0.05% SDS and then at 50_C for 30 min with 0.1× SSC/0.1% SDS. The brain region blot was washed at room temperature for 30 min with 2× SSC/0.5% SDS and then at 56_C for 30 min with 0.2× SSC/0.5% SDS. The blots were exposed to a phosphor screen for 24-72 h (Molecular Dynamics) and digitally composed. The multiple brain region experiment was performed three times and the multiple tissue experiment was performed twice with similar results. No signal was detected on blots probed with the reverse complement of the antisense probe. Blots were subsequently probed with an oligonucleotide specific to GAPDH (5′GCCCACAGCCTTGGCAGCACCAGTGGATGCA-GGGATGATGTTCCTG3′) to control for the amount of RNA loading in each lane.
